The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...
Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...
For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...
Headlines,Tandem Diabetes Care shares saw a significant rise after a crucial EU approval for its insulin delivery system.,The ...
Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...
New U.S. patent covers the design and composition of the BVP -- Positive results from ongoing preclinical studies support the potential of the ...
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...
Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the ...
It can be used by adults with Type 1 or Type 2 diabetes. Eversense 365 has an integrated CGM designation, meaning it can be used as part of an automated insulin delivery system, when a CGM and insulin ...